The DOI matches its Crossref record.
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients
Open accessAbstract
BACKGROUND: Hepatitis C virus (HCV) infection is highly prevalent and is associated with substantial morbidity and mortality among persons infected with the human immunodeficiency virus (HIV). We compared the efficacy and safety of pegylated interferon alfa-2a (peginterferon alfa-2a) plus either ribavirin or placebo with those of interferon alfa-2a plus ribavirin for the treatment of chronic HCV infection in patients who were also infected with HIV. METHODS: A total of 868 persons who were infected with both HIV and HCV and who had not previously been treated with interferon or ribavirin were randomly assigned to receive one of three regimens: peginterferon alfa-2a (180 microg per week) plus ribavirin (800 mg per day), peginterferon alfa-2a plus placebo, or interferon alfa-2a (3 million IU three times a week) plus ribavirin. Patients were treated for 48 weeks and followed for an additional 24 weeks. The primary end point was a sustained virologic response (defined as a serum HCV RNA level below 50 IU per milliliter at the end of follow-up, at week 72). RESULTS: The overall rate of sustained virologic response was significantly higher among the recipients of peginterferon alfa-2a plus ribavirin than among those assigned to interferon alfa-2a plus ribavirin (40 percent vs. 12 percent, P<0.001), or peginterferon alfa-2a plus placebo (40 percent vs. 20 percent, P<0.001). Among patients infected with HCV genotype 1, the rates of sustained virologic response were 29 percent with peginterferon alfa-2a plus ribavirin, 14 percent with peginterferon alfa-2a plus placebo, and 7 percent with interferon alfa-2a plus ribavirin. The corresponding rates among patients infected with HCV genotype 2 or 3 were 62 percent, 36 percent, and 20 percent. Neutropenia and thrombocytopenia were more common among patients treated with regimens that contained peginterferon alfa-2a, and anemia was more common among patients treated with regimens containing ribavirin. CONCLUSIONS: Among patients infected with both HIV and HCV, the combination of peginterferon alfa-2a plus ribavirin was significantly more effective than either interferon alfa-2a plus ribavirin or peginterferon alfa-2a monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021
Linas, B. P., Wong, A. Y., Schackman, B. R., Kim, A. Y., & Freedberg, K. A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis382 · Cited by 61
Camphor-based symmetric diimines as inhibitors of influenza virus reproduction
Sokolova, A. S., Yarovaya, О. I., Korchagina, D. V., Zarubaev, V. V., Tretiak, T. S., Anfimov, P. M., Kiselev, O. I., & Salakhutdinov, N. F. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.02.038 · Cited by 55
Fumaz, C. R., Muñoz-Moreno, J. A., Ballesteros, A. L., Paredes, R., Ferrer, M. J., Salas, A., Fuster, D., Masmitjà, E., Pérez-Álvarez, N., Gómez, G., et al. (2007) · AIDS Care · doi:10.1080/09540120600645539 · Cited by 30
Taylor, L. E., DeLong, A. K., Maynard, M. A., Chapman, S., Gholam, P., Blackard, J. T., Rich, J., & Mayer, K. H. (2011) · AIDS Patient Care and STDs · doi:10.1089/apc.2011.0106 · Cited by 24
Lanièce Delaunay, C., Klein, M. B., Godin, A., Cox, J., Kronfli, N., Lebouché, B., Doyle, C., & Maheu-Giroux, M. (2023) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2023.104026 · Cited by 9
Metadata
- Authors
- Torriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., Lissen, E., Gonzalez-García, J., Lazzarin, A., Carosi, G., Sasadeusz, J., Katlama, C., Montaner, J., Sette, H., Passe, S., De Pamphilis, J., Duff, F., Schrenk, U. M., & Dieterich, D. T.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-07-29
- Volume
- 351
- Issue
- 5
- Pages
- 438-450
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1996434966
- Cited by
- 1,233
- References
- 0
- FWCI
- 83.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
